Paladin Labs Announces the Canadian Launch of Travelan®

MONTREAL, Aug. 5, 2014 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo 
International plc   (NASDAQ: ENDP) (TSX: ENL), announced today the launch of 
Travelan®, a unique over-the-counter product to help reduce the risk of 
travellers' diarrhea. 
Travelan® is clinically proven to provide protection against the main cause 
of travellers' diarrhea in 90% of consumers who use it(1). Travelan® is a 
convenient option for all those travelling to at-risk regions such as Central 
and South America, Mexico, Africa, the Middle East and Asia. It does not 
require a prescription, and is not associated with any significant side 
It is estimated that there are over 5 million trips made by Canadians to 
at-risk regions every year(2). One-in-three Canadian vacationers have 
experienced, or have travelled with someone who has experienced, travellers' 
diarrhea(3). Sources of Enterotoxigenic Escherichia Coli (ETEC) bacteria, 
which cause the majority of cases of travellers' diarrhea(4), can include 
poorly cooked meat, contaminated raw vegetables or unpasteurized dairy 
products. Given that no food group can be regarded as "safe"(4), research 
demonstrates that three-quarters of Canadians have indicated that they would 
take a preventive for travellers' diarrhea(3). 
"We are pleased to announce the launch of Travelan® in Canada," said Mark 
Beaudet, President of Paladin Labs Inc. "This option responds to the clear 
market need for a clinically proven, accessible option to help reduce the risk 
of travellers' diarrhea." 
Paladin obtained the exclusive rights to market and sell Travelan(® )in 
Canada, Latin America (including Brazil and Mexico) and Sub-Saharan Africa 
(including South Africa) from Immuron Ltd (ASX:IMC) in November 2011. 
About Travelan(®) 
Travelan(®) is a natural product which is specifically designed to reduce the 
risk of infection by ETEC, the most common cause of travellers' diarrhea. In 
clinical trials, Travelan(®) showed efficacy of up to 90% in protecting 
against infection with the type of E.Coli that causes travellers' diarrhea. In 
addition, trials showed a significant reduction in abdominal cramps and 
stomach pain compared to those who did not receive Travelan(®). There were no 
reported treatment-related side effects in the clinical trials. 
For more information, please visit 
Suggested retail price: $29.99-39.99 (pack of 30 tablets). 
Available on pharmacy shelves. 
About Paladin Labs Inc. 
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty 
pharmaceutical company focused on acquiring or in-licensing innovative 
pharmaceutical products for the Canadian market. Paladin has a focused 
marketing and sales organization that has helped it evolve into one of 
Canada's leading specialty pharmaceutical companies. Paladin is an operating 
company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global 
specialty healthcare company focused on improving patients' lives while 
creating shareholder value.  Learn more at 
(1 )Travelan Product Packaging, 2013. 
(2 )Statistics Canada, International Travel 2010, Catalogue no. 66-201-X. 
(3 )Leger Marketing, State of Vacation:  Canadians Perspectives on Travellers' 
Diarrhea, October 2011. 
(4 )Public Health Agency of Canada, Canada Communicable Disease Report: 
Statement on Travellers' Diarrhea, 15 March 2001. 
Forward-Looking Statements 
Cautionary Note Regarding Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of 
the Private Securities Litigation Reform Act of 1995 and Canadian securities 
legislation. Statements including words such as "believes," "expects," 
"anticipates," "intends," "estimates," "plan," "will," "may," "look forward," 
"intend," "guidance," "future" or similar expressions are forward-looking 
statements. Because these statements reflect Endo's current views, 
expectations and beliefs concerning future events, these forward-looking 
statements involve risks and uncertainties. Although Endo believe that these 
forward-looking statements and information are based upon reasonable 
assumptions and expectations, readers should not place undue reliance on them, 
or any other forward-looking statements or information in this news release. 
Investors should note that many factors, as more fully described in the 
documents filed by Endo and Endo Health Solutions Inc. ("EHSI") with 
securities regulators in the United States and Canada including under the 
caption "Risk Factors" in EHSI's Form 10-K, and Endo's Form 10-Q and Form 8-K 
filings, as applicable, with the Securities and Exchange Commission and by 
Endo with securities regulators in Canada on the System for Electronic 
Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein 
or therein, could affect Endo's future financial results and could cause 
Endo's actual results to differ materially from those expressed in 
forward-looking statements contained in EHSI's Annual Report on Form 10-K. The 
forward-looking statements in this press release are qualified by these risk 
factors. These are factors that, individually or in the aggregate, could cause 
Endo's actual results to differ materially from expected and historical 
results. Endo does not assume any obligation to publicly update any 
forward-looking statements, whether as a result of new information, future 
developments or otherwise, except as may be required under applicable 
securities law.

SOURCE  Endo International plc 
Investors/Media: Blaine Davis, +353-1-669-6635, (484) 216-7158; Investors: 
Jonathan Neely, (484) 216-6645; Media: Heather Zoumas-Lubeski, (484) 216-6829 
CO: Paladin Labs Inc.
ST: Canada
-0- Aug/05/2014 11:30 GMT
Press spacebar to pause and continue. Press esc to stop.